initial androgen treatment for progressive, metastatic or recurrent prostate cancer andrew loblaw...
TRANSCRIPT
![Page 1: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/1.jpg)
Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer
Andrew Loblaw BSc, MD, MSc, FRCPC, CIPDepartment of Radiation OncologySunnybrook Health Sciences Centre
January 28, 2011
![Page 2: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/2.jpg)
Objectives
1. To review the standard initial hormonal interventions for prostate cancer
2. To discuss the evidence behind the use of AA monotherapy
3. To review the published literature on the benefit of combined androgen blockade
4. To review emerging evidence on the benefit of bicalutamide CAB for prostate cancer
5. To review the evidence behind the timing of ADT6. To review the pros/cons of intermittent
androgen blockade
![Page 3: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/3.jpg)
Standard ADT
![Page 4: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/4.jpg)
Standard ADT*
Seidenfeld J Ann Int Med 2002; 132(7):566-77
(aberelix)
***
*
![Page 5: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/5.jpg)
Combined Androgen Blockade
![Page 6: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/6.jpg)
PCTCGIndiv Pt DataMeta-Analysis
8275 men, 27 trials88% D2
Overall Death Rate70.4 vs 72.4%ARR 2%
NSAA Death Rate72.4 vs 75.3%ARR 2.9%(p<0.005)
PCTCG. Lancet 2000;355:1491-8
![Page 7: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/7.jpg)
Schmitt et al Meta-Analysis
• 20 RCTs, 6320 men with prostate cancer
• Efficacy• 2 y OS: OR 1.16 (95% CI 1.00 – 1.33)• 5 y OS: OR 1.29 (95% CI 1.11 – 1.50)
• Toxicity • diarrhea (10% v 2%)• gastrointestinal pain (7% v 2%)• non-specific ophthalmologic events (29% v 5%)
Schmitt et al Urology 57:727-32, 2001
![Page 8: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/8.jpg)
![Page 9: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/9.jpg)
Anti-androgen Use Today
• Steroidal Antiandrogens• Ketoconazole• Cyproterone acetate• Non-steroidal Antiandrogens• Flutamide• Nilutamide• Bicalutamide
![Page 10: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/10.jpg)
CCO MAB Guideline
![Page 11: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/11.jpg)
![Page 12: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/12.jpg)
SideEffects
![Page 13: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/13.jpg)
Patient Decision Making
n = 10 men with prostate cancer on RT
“What potential survival advantage (at 5 years) would you expect to justify these additional side effects and the inconvenience of taking a daily pill”
1 (10%) < 1 % survival benefit at 5 y
5 (50%) 1-5% survival benefit at 5 y
3 (30%) 5-10% survival benefit at 5 y
1 (10%) 10-15% survival benefit at 5 y
![Page 14: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/14.jpg)
New Data
• Klotz et al.• Combined data from PCTCG and Schellhammer’s
RCT of bicalutamide + LHRH vs flutamide + LHRH– Same methods used to get FDA approval of capecitabine
in colon CA
RHR = HR (PCTCG) * HR (Schell)= HR(flut vs castration) * HR (bical vs flut)= HR (bical vs castration)= .80 (95% CI 0.66 - 0.98)
Klotz L, Schellhammer P. Clin Prostate Cancer. 2005 Mar;3(4):215-9.
![Page 15: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/15.jpg)
Docetaxel for HR Prostate Cancer
Tannock NEJM 2004 Petrylak NEJM 2004
HR 0.76 HR 0.80
16.5 mo
18.9 mo
![Page 16: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/16.jpg)
Relative Benefit vs Accepted Treatments
Potential benefit of bicalutamide CAB• Pound Series 5 year median survival from
diagnosis of metastatic disease• Bicalutamide CAB would increase median
OS 1.25y over castrate therapies alone (with HR 0.80)
Potential Costs• CAB pack $(3900) per 6 months• Docetaxel $20 000 per 6 months
![Page 17: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/17.jpg)
ASCO 2006 Update
An interim analysis of an RCT2 and a study that combined
data from an individual patient data metaanalysis and a
randomized active control study,3 were published since the
last guideline. Overall survival is greater with the addition of
an NSAA to medical or surgical castration, but increased
adverse effects may occur as a result.
Loblaw DA et al., JCO April 2007
![Page 18: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/18.jpg)
Akaza update• Double-blind RCT, N=205, 40% D2• CAB vs LHRHa (or CAB at progression)• Median F/U 5.2y
HR 0.78 (0.60 – 0.99)p=0.0498 or 0.0425y OS 75 vs 63%
CSS HR 0.79 (.55 – 1.11)
Akaza H et alCancer 115: 3437-45; 2009
![Page 19: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/19.jpg)
Summary CAB• Several meta-analyses have shown
small to moderate improvements in overall survival with CAB
• Two recent clinical practice guidelines recognize these improvements but are concerned about additive toxicity
• All studies in MA used older AA which are rarely used today
• Bicalutamide CAB has very tolerable side effects and has a large OS benefit
![Page 20: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/20.jpg)
Clinical Practice
“I think there is a compelling survival advantage with bicalutamide CAB and I will speak to my patients about that option”
or
“I am not convinced that there is a compelling survival advantage with bicalutamide CAB and a clinical trial should be designed to address the issue”
![Page 21: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/21.jpg)
Timing of ADTi) Watchful Waiting Patients
![Page 22: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/22.jpg)
• 1960-1975, n=954 locally advanced or metastatic disease
• Randomized to one of four arms: placebo, orch+placebo, DES (5mg), or orch+DES
• Patients with metastatic disease in the placebo arm were allowed active treatment upon progression
Jordan WP. South Med J 1977;70(12):1411-1413
VACURG I Study
12 year survival P Orch+P
DES Orch+DES
Cause specific (%) Overall (%)
6510
7012
7713
7613
![Page 23: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/23.jpg)
T3/4 or M1
Prostate Cancer
RANDOMIZE
n=934
MRC Prostate Cancer Working Party Investigators Group Br J Urol 1997;79:235-246
Immediate ADT
Deferred ADT (at symptom
onset)
n=469
n=465
•Distant Progression•Overall survival•Cause specific
survival•Pain-free survival•TURP•Ureteric obstruction•Metastatic
complication
Outcomes
MRC Study Schema
![Page 24: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/24.jpg)
Minimum follow-up of 2.7 years
3847267
4258
598645123746
Deferred(%) 2p
Immediate(%)
<0.001<0.001<0.001<0.025
0.020.001
n =934, T3/4 or M1
Distant progressionPainful metastasesTURPUrinary obstruction5 yr OS5 yr CSS
MRC Study Outcomes
MRC Prostate Cancer Working Party Investigators Group Br J Urol 1997;79:235-246
![Page 25: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/25.jpg)
Minimum follow-up of 9.5 years
74258
123746
Deferred(%) 2p
Immediate(%)
0.090.250.26
n =934, T3/4 or M1
Overall survivalExtraskeletal metastasesUrinary obstruction
MRC Study Outcomes
Kirk, 2004
![Page 26: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/26.jpg)
•No standardized follow-up schedule- 29 patients (6.2%) randomized to deferred arm
died of prostate cancer before receiving treatment
•Minority of patients had PSA measured on follow-up
•Generalizability?- Results from locally advanced or M1 tumors may not reflect biology of biochemical failures post-RT
MRC Criticisms
![Page 27: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/27.jpg)
LocalizedProstate Cancer
•Too unwell for
radical therapy
RANDOMIZE
Immediate Orchiectomy
Deferred Orchiectomy
(at symptom onset)
n=197
Studer et al. J Clin Oncol 2004;22:4109-4118
n=96
n=92
SAKK 08/88 Study Schema
•Cause specific survival
•Overall survival•First pain•Symptom-free
survival•Ureteric obstruction•New metastases
Outcomes
![Page 28: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/28.jpg)
OverallSurvival
Cause SpecificSurvival
Time to HormoneResistant Disease
SAKK 08/88 Results
![Page 29: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/29.jpg)
T0-4 N0-2 M0ProstateCancer
n=985
Studer UE et al. J Clin Oncol 2006;24:1868-76
n=493
n=492
Too unwell for radical therapy
ExcludedAge > 80 yrOther CA (non-BCC)Symptomatic Pr CA“juxtaregional LN”
Immediate ADT
Deferred ADT (at symptom
onset)
RANDOMIZE
EORTC 30891 Study Schema
•Overall survival•Cause specific
survival•Non-PC survival•Symptom-free
survival•Time to Dist Mets•Symptomatic AIPC•Castrate
Metastases•TURP
Outcomes
![Page 30: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/30.jpg)
Overall Hazard Ratio 1.25 (1.05-1.48)
Non-inferiority p = 0.47
36%
25%
68%
61%
SURVIVAL
p = 0.44
p = 0.062
925
1326
Deferred(%)
Immediate(%)
5 yr10 yr
Cause specificMortality
2339
2646
Deferred(%)
Immediate(%)
5 yr10 yr
All causeMortality
![Page 31: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/31.jpg)
Cause-Specific Mortality
Studer UE et al. Eur Urol 2008;53:914-9
Immediate Arm
Deferred Arm
By PSAdt in deferred arm
![Page 32: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/32.jpg)
Timing of ADTiii) N+ Post-Radical Prostatectomy Patients
![Page 33: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/33.jpg)
ECOG 3886N+ post rP
Messing E et al. N Engl J Med 1999;341:1781-8
![Page 34: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/34.jpg)
EORTC 30846N+, no rP
OS HR 1.23 [0.88-1.71]medOS 7.8 vs 6.2 y
CSS no difference
Difference w/ ECOG 3886• More T3 (66%)• No local treatment
![Page 35: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/35.jpg)
Timing of ADTiii) Recurrent Cancer Post-RT
![Page 36: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/36.jpg)
SathyaJCO
2005
PeetersJCO
2006
n=305
Dose Escalated Radiation Therapy
Pollack IJROBP 2002
Zeitman
JAMA2005
![Page 37: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/37.jpg)
Skarsgard D, Tonita J. Ca Cause Control 2000; Cdn Cancer Stats 2006
Burden of Problem
Extent of disease Incidence
Localized 17,225 (85%)
Metastatic 3,151 (15%)
![Page 38: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/38.jpg)
Skarsgard D, Tonita J. Ca Cause Control 2000; Cdn Cancer Stats 2006
97019411745
485970873
5 yr Biochemical Failure
Localized disease At risk(n)
Post-RT(n)
Burden of Problem
Low riskIntermediateHigh risk
Incidence
53914852 6982
(31%)(28%)(41%)
30% overall (2570 post-RT)
![Page 39: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/39.jpg)
Post-Radiotherapy Failure
• Local therapies– Radical prostatectomy– Cryotherapy– HiFU– Seed brachytherapy*
• ANDROGEN DEPRIVATION THERAPY– ASCO Androgen Sensitive Guideline
2006 Update available Jan 29th, 2007
![Page 40: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/40.jpg)
TROG Timing of Androgen Deprivation (TOAD)•ongoing
RCTs Timing of ADT Post Radical RT
![Page 41: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/41.jpg)
Skarsgard D, Tonita J. Ca Cause Control 2000; Cdn Cancer Stats 2006
<1010-2020-50>50
20183224
2850202
2000USA
5336110
1994Canada
2004Canada
Trigger PSA (ng/mL)for starting ADT
Patterns of Care Survey
Oncologists Survey (%)
![Page 42: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/42.jpg)
Hormone-Sensitive Prostate Cancer (2004)
• Timing of ADT • Systematic review of literature
– 1 meta-analysis– 1 Markov model
Loblaw DA et al. J Clin Oncol 2004;14:2927-41
ASCO Guidelines
![Page 43: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/43.jpg)
“...antiandrogen in addition to castrate therapy. Until data from studies using modern medical diagnostic/biochemical
tests and standardized follow-up schedules become available, no specific recommendations can be issued regarding the
question of early versus deferred ADT. A discussion about the pros and cons of early versus deferred ADT should occur.”
Loblaw DA et al J Clin Oncol 2004;14:2927- 41
ASCO Guidelines
![Page 44: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/44.jpg)
Meta-Analysis of Literature
Inclusion criteria– RCTs on patients with metastatic or untreated localized prostate cancer– ADT Intervention
Literature search– Medline 1966 – Mar 2006– Cochrane Database of Systemic Reviews
Exclusion Criteria– Patients previously treated with ADT– Patients undergoing primary RT with ADT
![Page 45: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/45.jpg)
Meta-Analysis of Literature
Methods of analysis– Outcomes: all cause death, prostate cancer mortality
– RevMan 4.2.8
– Visual and statistical evaluation of heterogeneity
– Combined Relative Ratio, 95% confidence intervals
– Sensitivity analyses performed for methodological weakness, heterogeneity
![Page 46: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/46.jpg)
Prostate Cancer Mortality
![Page 47: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/47.jpg)
Overall Mortality
![Page 48: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/48.jpg)
“Until data from studies using modern medical diagnostic/ biochemical tests and standardized follow-up schedules become available, no specific recommendations can be issued regarding the question of early versus deferred ADT. A discussion about the pros and cons of early versus deferred ADT should occur.”
Loblaw DA et al J Clin Oncol 2004;14:2927- 41
ASCO Guidelines
Loblaw DA et al J Clin Oncol April 2006
“In metastatic or progressive PCa, immediate versus symptom-onset institution of ADT results in a moderate decrease (17%) in relative risk (RR) for PCa-specific mortality, a moderate increase (15%) in RR for non–PCa-specific mortality, and no overall survival advantage. Therefore, the Panel cannot make a strong recommendation for early ADT initiation.… For patients electing to wait until symptoms for ADT, regular monitoring visits are indicated.”
![Page 49: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/49.jpg)
1. What are the benefits of immediate
ADT following radiation therapy
Unanswered Questions
−Can we extrapolate from
Watchful Waiting / Metastatic
patient data?2. What is the magnitude of detriment on QOL?
![Page 50: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/50.jpg)
• Vasomotor symptoms
• Decreased libido erectile
dysfunction
• Decreased muscle mass
• Decreased energy
• Metabolic syndrome
• Osteopenic effects
ADT Side Effects
![Page 51: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/51.jpg)
• 50,613 men with Prostate Cancer in SEERdatabase 1992-1997
• 19% vs 12% had (any) fracture (living >5 yr)─ bone metastases not excluded
![Page 52: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/52.jpg)
• 73,197 men > 66 yr in SEER, Medicare• 1/3 had LHRH agonist• Excluded prevalent M1, DM, CAD
In 10 years 9% 11% 3% 4%
![Page 53: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/53.jpg)
Prognostic Factors
OverallMortality
DistantMetastases
PredictorsCause specific
Mortality
D’Amico2006
PSAdt (< 6months)
Gleason Score (8-10)
PSA response to ADT
Age < 75yr
Kim-Sing2004
Pound1999
Pound1999
D’Amico2006
D’Amico2006
3. Does the effect of timing of ADT differ by PSAdt, Gleason?
![Page 54: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/54.jpg)
Timing of ADT for Recurrent Prostate
Cancer
![Page 55: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/55.jpg)
96 Canadian Specialists – 42 GU Radiation Oncologists– 50 Urologists– 4 Medical Oncologists
ELAAT Survey
Current Practice– Trigger: PSAdt (28%), PSA (3%), both (69%)– Start treatment if PSAdt < 12months (95%) – Start treatment if PSA (ng/mL) <10 (53%), 10-20
(36%)– Orchiectomy (0%)
![Page 56: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/56.jpg)
Trial comfort zones to start ADT– Lowest PSA to start ADT: 4ng/mL (58%)
5ng/mL (86%)
– Highest PSA to withhold ADT: 25ng/mL (61%)
– PSAdt trigger: < 12 months (71%)
ELAAT Survey
Need for Trial– Moderate to very important (86%)– Very important (51%)– Number of patients per year: 1500+
![Page 57: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/57.jpg)
Andrew Loblaw, Sergio Faria, Himu Lukka, Tom Pickles,
Patrick Cheung, Lawrence Klotz, Kathy Pritchard,
Martin Gleave, Tulay Koru-Singul, Mark Levine
A Randomized Comparison of Immediate versusDeferred Androgen Deprivation Therapy using
Goserelin for Recurrent Prostate Cancer after Radical Radiotherapy
ELAAT STUDY
![Page 58: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/58.jpg)
LocalizedProstate Cancer
Asymptomatic biochemical failure post RT
RANDOMIZE
Immediate LHRH
Deferred LHRH
(at symptom onset)
(or PSA>25ng/mL)
•Time to Androgen Independent Disease
•Cause specific survival
•Overall survival•Quality of Life•Complications of
Advanced Malignancy•Bone Fractures
Outcomes
ELAAT Study Schema
![Page 59: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/59.jpg)
ELAAT Enrolment
PSAdt
Gleason Score
Immediate LHRH
Deferred LHRH
Randomization
n= 1100
Clinical Trial Centre
≤12months >12months
2-7 8-102-7 8-10
Centre
![Page 60: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/60.jpg)
1. Adults (> 18 years old) with histopathologically confirmed adenocarcinoma of the prostate
2. Patients who have failed biochemically after radical radiation therapy (total prostate dose ≥52 Gy)
3. PSA <6 ng/mL within 30 days of randomization
ELAAT Inclusion Criteria
![Page 61: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/61.jpg)
1. Patients who have had a primary or salvage radical prostatectomy, salvage cryotherapy, thermal ablation, photodynamic therapy or high intensity focus ultrasound
2. Patients who are within 4 years of their brachytherapy implantation date
3. Patients with medical conditions in which goserelin or bicalutamide is contraindicated in the opinion of the supervising oncologist or urologist
4. Patients with another active malignancy or malignancy treatment within 5 years (except for basal or squamous cell skin cancers)
5. Patients who are geographically inaccessible for follow-up
6. Patients who fail to provide written informed consent
ELAAT Exclusion Criteria
![Page 62: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/62.jpg)
1.Bicalutamide 50 mg po OD days 1-30 (may
be given continuously at the discretion of supervising oncologist)
2.Goserelin 10.8 mg SC day 10-17 + q3months until patient discontinuation
ELAAT Treatment
![Page 63: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/63.jpg)
ELAAT Outcomes
•Time to androgen independent disease (AID)
•Cause specific survival•Overall survival•Quality of Life•Complications of advanced malignancy
(CAM)•Bone Fractures
![Page 64: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/64.jpg)
ELAAT Follow-Up
Physical exam + digital rectal examination
CBC, Testosterone, PSA (within 30days of randomization)
Quality of Life
Goserelin compliance
√
√
√
During the last 6 months:Fractures
Need for palliative radiotherapy, palliative surgery, TURP, spinal cord compression or ureteric obstruction
Chemotherapy, antiandrogens, bisphosphonates, calcium, vitamin D or erythropoietinDual x-ray absorption (DEXA) scan √*
Baseline q 6months
√
√
√
√
√
√
√
√**
* within 1 month of 1st injection, ** every 2 years after 1st injection of goserelin
![Page 65: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/65.jpg)
ELAAT Statistical Considerations
Sample size determination – A non-inferiority time to event analysis based on
two exponential survival curves
Assumptions on sample size calculation – Androgen independent disease at 10 years =
30% for immediate LHRH group– True difference 7.5% (i.e. Hazard Ratio = 1.318)– (Deferred LHRH - Immediate LHRH) < 7.5%– Alpha 2.5% – Power 80%
Total 1064 patients (n=532/per arm)– Total recruitment will be 1100 patients
(n=550/per arm) to account for 3.2% lost to follow-up
![Page 66: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/66.jpg)
Canadian survey: 1500 eligible patients per year
Accrual estimate: 225 patients for 1st year 450 patients for subsequent
years
Complete accrual: 3-4 years
First analysis: at 7 years median follow-up
ELAAT Study Timelines
Contract Signed Jun 2006
Health Canada CTA NOL Aug 2006
Ontario Cancer REB Approval Nov 2006
Study Activation Aug 2007
![Page 67: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/67.jpg)
Clinical Practice
• “After RT failure, I don’t think there is a compelling survival advantage with early ADT and I recommend not starting ADT until symptoms arise”
• or• “I don’t know when ADT should be
started after RT failure and I would support a clinical trial designed to address the issue”
![Page 68: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/68.jpg)
Summary
• Recurrent prostate cancer after radical treatment a common problem
• Well characterized toxicity profile but…– Conflicting evidence for WW and CSS
benefit– No evidence for N0 post rP or RT– Benefit in OS, CSS for N+ after rP?
• Further study in development
![Page 69: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/69.jpg)
Intermittent Androgen Blockade
• N = 766 (626 enrolled), locally advanced / M1
• 3 mo IAB (CPA + LH) vs CAB• Trigger: PSA < 4 ng/ml (or 80% reduction)• mFU 51 mo• Progression: HR 0.81 (0.63 – 1.05, p=0.11)• OS: 0.99 (0.80 – 1.23)• Improved QOL• 52 wk median off-treatment IAB
Calais da Silva FEC Eur Urol 55:1269-77;2009
![Page 70: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/70.jpg)
![Page 71: Initial Androgen Treatment for Progressive, Metastatic or Recurrent Prostate Cancer Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology](https://reader030.vdocuments.net/reader030/viewer/2022032709/56649eda5503460f94be9ce5/html5/thumbnails/71.jpg)
IAB Cont’d
• NCIC PR7 press release May 2010 – failed to reach primary endpoint
• IAB practiced commonly• ? Sufficient evidence to change
guidelines